Criteria Bio Ventures
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.
NRG Therapeutics
8 Sept 2025
NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies
NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.
Criteria Bio Ventures
More venture news
- 23 Jun 2026
Astral SystemsAstral Systems unlocks £23m Series A led by Mercia Ventures to develop medical isotopes with multi-state fusion technology
Series ADeep Tech - 22 Jun 2026
SuperlightSuperlight secures £16m Series A led by Engine Ventures and 2150 to manufacture electric commercial vehicles for middle mile logistics
Series AMobility - 22 Jun 2026
IsometricIsometric raises £30m in a Series A led by AVP to automate industrial certification with AI agents
Series AIndustrial
